Binding molecules for bcma and cd3

The binding molecule according to any one of the preceding claims, wherein the first binding domain comprises a VH region selected from the group consisting of VH regions as depicted in SEQ ID NO:

• 237, SEQ ID NO:
• 247, SEQ ID NO:
• 257, SEQ ID NO:
• 267, SEQ ID NO:
• 277, SEQ ID NO:
• 287, SEQ ID NO:
• 297, SEQ ID NO:
• 307, SEQ ID NO:
• 397, SEQ ID NO:
• 407, SEQ ID NO:
• 417, SEQ ID NO:
• 427, SEQ ID NO:
• 437, SEQ ID NO:
• 447, SEQ ID NO:
• 457, SEQ ID NO:
• 467, SEQ ID NO:
• 477, SEQ ID NO:
• 487, SEQ ID NO:
• 497, and SEQ ID NO:
• 507.

A method for the generation of an antibody, preferably a binding molecule, which is capable of binding to BCMA, comprising

• (a) immunizing an animal with a polypeptide comprising epitope cluster 3 and epitope cluster 4 of BCMA, wherein epitope cluster 3 of BCMA corresponds to amino acid residues 24 to 41 of the sequence as depicted in SEQ ID NO:
• 1002, and epitope cluster 4 of BCMA corresponds to amino acid residues 42 to 54 of the sequence as depicted in SEQ ID NO:
• 1002,
• (b) obtaining said antibody, and
• (c) optionally converting said antibody into a binding molecule which is capable of binding to human BCMA and preferably to the T cell CD3 receptor complex.